In yesterday’s Wall Street session, CVS Health Corp (NYSE:CVS) shares traded at $59.19, up 0.19% from the previous session.
CVS stock price is now -0.27% away from the 50-day moving average and -5.19% away from the 200-day moving average. The market capitalization of the company currently stands at $74.49B.
With the price target maintained at $66, Deutsche Bank recently Upgraded its rating from Hold to Buy for CVS Health Corp (NYSE: CVS). On November 18, 2024, Wells Fargo Upgraded its previous ‘Equal Weight’ rating to ‘Overweight’ on the stock increasing its target price from $60 to quote $66, while ‘Barclays’ rates the stock as ‘Overweight’
In other news, LUDWIG EDWARD J, Director bought 1,000 shares of the company’s stock on May 02 ’24. The stock was bought for $53,879 at an average price of $53.88. Upon completion of the transaction, the Director now directly owns 21,630 shares in the company, valued at $1.28 million. An SEC document containing details of the transaction can be found on the SEC’s website. On May 02 ’24, Director Mahoney Michael F bought 9,181 shares of the business’s stock. A total of $500,294 was incurred on buying the stock at an average price of $54.49. This leaves the insider owning 9,356 shares of the company worth $0.55 million. A total of 0.19% of the company’s stock is owned by insiders.
During the past 12 months, CVS Health Corp has had a low of $52.71 and a high of $83.25. As of last week, the company has a debt-to-equity ratio of 1.10, a current ratio of 0.80, and a quick ratio of 0.59. The fifty day moving average price for CVS is $59.3192 and a two-hundred day moving average price translates $62.5214 for the stock.
The latest earnings results from CVS Health Corp (NYSE: CVS) was released for 2024-09-30. The net profit margin was 1.36% and return on equity was 6.72% for CVS. The company reported revenue of $95.43 billion for the quarter, compared to $89.76 billion a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 6.31 percent.
